Skip to content
DataLookout
Menu

eDetect-mCRCNCT05068531

Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Recruiting
  2. Minor Collaborators shortened, about 15 wordsv4
  3. Minor Start date changed from estimate of Jun 2022 to Sep 1, 2022v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2021 to Jun 2022
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Radiological response to pre-operative chemotherapy as assessed by RECIST v1.1
Timeframe: Approximately three months
Biochemical response to pre-operative chemotherapy as assessed by plasmatic CEA measurement, change from baseline after 4 cycles of chemotherapy
Timeframe: Approximately three months
Pathological response to pre-operative chemotherapy as assessed by Ryan and Rubbia Brandt Tumor Regression Grade (TRG) scores on resected tumors
Timeframe: Approximately three months
Tumor response to pre-operative chemotherapy as assessed by change in circulating tumor DNA level, change from baseline
Timeframe: Approximately three months
Histopathologic growth pattern as assessed by percent replacement, desmoplastic, and pushing features measured at the interface of liver metastasis and non tumoral liver
Timeframe: Three to four months
Post-operative minimal residual disease as assessed by circulating tumor DNA detection after tumor resection with curative intent
Timeframe: Approximately 1 months after resection with curative intent
Time to radiological recurrence after tumor resection with curative intent
Timeframe: Up to three years after tumor resection with curative intent
Time to biochemical recurrence as assessed by plasmatic CEA measurement, level above the upper limit occurring after tumor resection with curative intent
Timeframe: Up to three years after tumor resection with curative intent
Time to tumor recurrence as assessed by detection or change in level of circulating tumor DNA after tumor resection with curative intent
Timeframe: Up to three years after tumor resection with curative intent

Secondary (5)

Incidence and grade of FOLFOX-induced neuropathy, as assessed by Sensory Subscale of the NCI CTCAE scale, version 3
Incidence of allergic reaction to oxaliplatin diagnosed by treating physicians and requiring desensitization or change in chemotherapy regimen
Incidence of hospitalization for febrile neutropenia diagnosed by treating physicians
Ninety-day post-surgical complications, defined by Clavien Dindo grading system
Disease-specific survival after complete tumor resection

Arms and interventions

Observational

We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.

Sites

1 site in 1 country

  • Centre hospitalier de l'Université de Montréal (CHUM)Montreal, Quebec, Canada